iSpecimen to Report Fourth Quarter and Full Year 2021 Results on February 17, 2022
February 03 2022 - 7:30AM
iSpecimen Inc. (NASDAQ: ISPC) (“iSpecimen”
or the “Company”), an online marketplace for human
biospecimens, today announced that it will report its financial
results for the fourth quarter and full year ended December 31,
2021, before the markets open on Thursday, February 17, 2022.
The Company will host a conference call and audio
webcast that morning at 8:30 a.m. Eastern Time featuring remarks by
Christopher Ianelli, MD, PhD, CEO and President, Tracy Curley, CFO
and Treasurer, and Jill Mullan, COO and Secretary.
Event: |
iSpecimen Fourth Quarter and
Full Year 2021 Results Conference Call |
Date: |
Thursday, February 17,
2022 |
Time: |
8:30 a.m. Eastern Time |
Live
Call: |
+1-877-425-9470 (U.S. Toll
Free) or + 1-201-389-0878 (International) |
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1526504&tp_key=09d0a0a925 |
For interested individuals unable to join the conference call, a
replay will be available through March 3, 2022, at +1-844-512-2921
(U.S. Toll Free) or +1-412-317-6671 (International). Participants
must use the following code to access the replay of the call:
13726694. An archived version of the webcast will also be available
on iSpecimen’s Investor Relations site:
https://ispecimen.irpass.com/.
About iSpecimeniSpecimen offers an online
marketplace for human biospecimens, connecting life scientists in
commercial and non-profit organizations with healthcare providers
that have access to patients and specimens needed for medical
discovery. Proprietary, cloud-based technology enables scientists
to intuitively search for specimens and patients across a federated
partner network of hospitals, labs, biobanks, blood centers, and
other healthcare organizations. For more information about
iSpecimen, please visit www.ispecimen.com.
Forward Looking StatementsThis press release
may contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," believe," "estimate" and "continue" or similar words.
You should read statements that contain these words carefully
because they discuss future expectations and plans, which contain
projections of future results of operations or financial condition
or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risks factors contained
in the Company's filings with the Securities and Exchange
Commission, which are available for review at www.sec.gov.
Forward-looking statements speak only as of the date they are made.
New risks and uncertainties arise over time, and it is not possible
for the Company to predict those events or how they may affect the
Company. If a change to the events and circumstances reflected in
the Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
statements.
Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Investor ContactKCSA Strategic
CommunicationsAllison SossiSpecimen@kcsa.com
Media ContactKCSA Strategic
CommunicationsRaquel ConaiSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Apr 2023 to Apr 2024